ClinicalTrials.gov
ClinicalTrials.gov Menu

Dexamethasone and Block Duration in Upper Extremity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01756573
Recruitment Status : Unknown
Verified March 2014 by University of Chicago.
Recruitment status was:  Recruiting
First Posted : December 27, 2012
Last Update Posted : March 31, 2014
Sponsor:
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not.

Condition or disease Intervention/treatment Phase
Duration of Pain Relief Drug: Dexamthsone Drug: Bupivacaine Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study of the Effect of Dexamethasone on Duration of Upper Extremity Blocks With Bupivacaine
Study Start Date : January 2013
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : December 2014


Arm Intervention/treatment
Active Comparator: Bupivacaine
Control
Drug: Bupivacaine
Experimental: Bupivacaine with Dexamethasone
Dexamethasone will be mixed with bupivacaine
Drug: Dexamthsone
Drug: Bupivacaine
Active Comparator: Intravenous Dexamethasone
Dexamethasone will be given intravenously
Drug: Dexamthsone
Drug: Bupivacaine



Primary Outcome Measures :
  1. analgesia duration [ Time Frame: 72 hrs ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 18-75, no contraindication to regional anesthesia,

Exclusion Criteria:

  • opioid user, chronic pain conditions, peripheral neuropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01756573


Contacts
Contact: Tariq Malik tmalik@dacc.uchicago.edu

Locations
United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Tariq Malik, MD         
Sponsors and Collaborators
University of Chicago

Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT01756573     History of Changes
Other Study ID Numbers: IRB12-2192
First Posted: December 27, 2012    Key Record Dates
Last Update Posted: March 31, 2014
Last Verified: March 2014

Keywords provided by University of Chicago:
block duration
analgesia

Additional relevant MeSH terms:
Dexamethasone acetate
Dexamethasone
Bupivacaine
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents